However, like drugs targeting glycolysis (Pelicano et al., 2006), the anticancer efficacy of GLUT1 inhibitors may not be sufficient as single agents, and proper combination with other anticancer drugs may be required to effectively kill cancer cells. Here, SLC2A1 is linked to cancer.